CONTENTS

SHORT COMMUNICATION


ACCELERATED COMMUNICATION

Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor. Edna F. Choo, Sarah Woolsey, Kevin DeMent, Justin Ly, Kirsten Messick, Ann Qin, and Ryan Takahashi ......................... 864

ARTICLES

Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Conjugate. Craig Giragossian, Chandra Vage, Jun Li, Kathleen Pelletier, Nicole Piché-Nicholas, Manoj Rajadhyaksha, Jennifer Liras, Alison Logan, Roberto A. Calle, and Yan Weng. ................................. 803


Short-Term Fasting Alters Cytochrome P450–Mediated Drug Metabolism in Humans. Laureen A. Lammers, Roos Achterbergh, Emmely M. de Vries, F. Samuel van Nierop, Heinz-Josef Klümpen, Maarten R. Soeters, Anita Boelen, Johannes A. Romijn, and Ron A. A. Mathôt. ................................. 819


Prediction of Gestational Age–Dependent Induction of In Vivo Hepatic CYP3A Activity Based on HepaRG Cells and Human Hepatocytes. Zafei Zhang, Muhammad Farooq, Bhagwat Prasad, Sue Grepper, and Jashvant D. Unadkat ................................. 836

The Effects of Endoxifen and Other Major Metabolites of Tamoxifen on the Sulfation of Estradiol Catalyzed by Human Cytosolic Sulfotransferases hSULT1E1 and hSULT1A1*1. Edwin J. Squirewell and Michael W. Duffel ................................. 843

Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans. Xiaoyan Chu, Shian-Jiun Shih, Rachel Shaw, Hannes Hentze, Grace H. Chan, Karen Owens, Shubing Wang, Xiaoxin Cai, Deborah Newton, Jose Castro-Perez, Gino Salturo, Jairam Palamanda, Aaron Fernandis, Choon Keow Ng, Andy Liaw, Mary J. Savage, and Raymond Evers ................................. 851

Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model. Boyd Steere, Jessica A. Roseberry Baker, Stephen D. Hall, and Yingying Guo ................................. 870

Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells. Apichaya Chanawong, Dong Gui Hu, Robyn Meech, Peter I. Mackenzie, and Ross A. McKinnon .......... 889

Continued on next page